Compare Fabrinet (FN) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Fabrinet (FN) trades at $487.33, down 2.14% on the day, yet maintains a bullish technical stance with strong analyst support. The stock shows robust fundamentals, with Q2 2026 EPS of $4.10 beating estimates and revenue growth accelerating to $4.6B in 2026. Positive sentiment is driven by surging AI data-center demand, though the stock faces near-term pressure from high valuations and capital expenditure concerns.

Outlook remains positive given FN's strategic position in AI infrastructure and capacity expansion, with a consensus price target of $769.50 implying significant upside. Key risks include customer concentration, margin pressure from spending, and sensitivity to tech sector volatility. The combination of strong earnings momentum and Wall Street optimism supports a constructive view for long-term investors.

INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.

Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.